Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.36 |
| ▸ | MEN1 | O00255 | 3/20 | 0.36 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.36 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.36 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.36 |
| ▸ | FLT1 | P17948 | 1/20 | 0.36 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 3/20 | 0.36 |
| ▸ | GALR2 | O43603 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7593494 | 0.88 | TPMT (0.41) | MAPTKMT2AMEN1LMNAGAA | |
| SCHEMBL7598494 | 0.88 | KMT2A (0.38) | SMN1; SMN2MAPTKMT2AMEN1LMNA | |
| SCHEMBL7596330 | 0.87 | LMNA (0.36) | SMN1; SMN2MAPTKDM4EKMT2AMEN1 | |
| SCHEMBL7596324 | 0.86 | KMT2A (0.46) | SMN1; SMN2KMT2AMEN1LMNAGALR2 | |
| SCHEMBL7594307 | 0.85 | KMT2A (0.38) | SMN1; SMN2VCAM1MAPTKDM4EKMT2A | |
| SCHEMBL7960036 | 0.82 | ALDH1A1 (0.40) | SMN1; SMN2MAPTKDM4ELMNAGALR2 | |
| SCHEMBL7594081 | 0.82 | ALDH1A1 (0.52) | SMN1; SMN2MAPTKMT2AMEN1LMNA | |
| SCHEMBL7593978 | 0.81 | IMPDH2 (0.39) | SMN1; SMN2MAPTKMT2AMEN1LMNA | |
| SCHEMBL7822145 | 0.81 | GAA (0.40) | SMN1; SMN2KDM4EKMT2AMEN1POLB | |
| SCHEMBL7593974 | 0.79 | IMPDH2 (0.35) | SMN1; SMN2MAPTKMT2AMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6455698-B1 | FOR TREATING CEREBRAL ISCHEMIA OR CEREBRAL INFARCTION RESULTING FROM THROMBOEMBOLIC OR HEMORRHAGIC STROKE, CEREBRAL VASOSPASMS, HYPOGLYCEMIA, CARDIAC ARREST, NEURODEGENERATIVE DISORDERS | WARNER-LAMBERT COMPANY | 2002-09-24 | — | — | US | disclosed |
| US-20020065415-A1 | Conformationally semi-constrained quinoxaline 2,3-diones as neuroprotective agents | KORNBERG BRIAN EDWARD (US) | 2002-05-30 | — | — | US | disclosed |
| US-6340758-B1 | DRUGS AS NEUROPROTECTIVE AGENTS INVENTION MAY ALSO BE USEFUL IN THE TREATMENT OF SCHIZOPHRENIA, EPILEPSY, ANXIETY, PAIN AND DRUG ADDICTION. | WARNER-LAMBERT COMPANY | 2002-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020065415-A1 | Conformationally semi-constrained quinoxaline 2,3-diones as neuroprotective agents | CBR1, CBR3, CHRNA7 | SMN1; SMN2 201/4885VCAM1 2893/4885MAPT 3487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.